S&P 500   3,400.97 (-1.86%)
DOW   27,685.38 (-2.29%)
QQQ   280.47 (-1.50%)
AAPL   115.05 (+0.01%)
MSFT   210.08 (-2.84%)
FB   277.11 (-2.70%)
GOOGL   1,584.29 (-2.98%)
AMZN   3,207.04 (+0.08%)
TSLA   420.28 (-0.08%)
NVDA   525.65 (-3.30%)
BABA   306.87 (-0.98%)
CGC   18.53 (-6.08%)
GE   7.38 (-3.28%)
MU   52.14 (-1.34%)
AMD   82.23 (+0.33%)
T   27.38 (-1.58%)
F   8.03 (-1.59%)
ACB   4.40 (-5.98%)
GILD   59.96 (-1.37%)
NFLX   488.24 (+-0.01%)
NIO   26.01 (-4.23%)
BA   160.83 (-3.90%)
DIS   124.06 (-3.34%)
S&P 500   3,400.97 (-1.86%)
DOW   27,685.38 (-2.29%)
QQQ   280.47 (-1.50%)
AAPL   115.05 (+0.01%)
MSFT   210.08 (-2.84%)
FB   277.11 (-2.70%)
GOOGL   1,584.29 (-2.98%)
AMZN   3,207.04 (+0.08%)
TSLA   420.28 (-0.08%)
NVDA   525.65 (-3.30%)
BABA   306.87 (-0.98%)
CGC   18.53 (-6.08%)
GE   7.38 (-3.28%)
MU   52.14 (-1.34%)
AMD   82.23 (+0.33%)
T   27.38 (-1.58%)
F   8.03 (-1.59%)
ACB   4.40 (-5.98%)
GILD   59.96 (-1.37%)
NFLX   488.24 (+-0.01%)
NIO   26.01 (-4.23%)
BA   160.83 (-3.90%)
DIS   124.06 (-3.34%)
S&P 500   3,400.97 (-1.86%)
DOW   27,685.38 (-2.29%)
QQQ   280.47 (-1.50%)
AAPL   115.05 (+0.01%)
MSFT   210.08 (-2.84%)
FB   277.11 (-2.70%)
GOOGL   1,584.29 (-2.98%)
AMZN   3,207.04 (+0.08%)
TSLA   420.28 (-0.08%)
NVDA   525.65 (-3.30%)
BABA   306.87 (-0.98%)
CGC   18.53 (-6.08%)
GE   7.38 (-3.28%)
MU   52.14 (-1.34%)
AMD   82.23 (+0.33%)
T   27.38 (-1.58%)
F   8.03 (-1.59%)
ACB   4.40 (-5.98%)
GILD   59.96 (-1.37%)
NFLX   488.24 (+-0.01%)
NIO   26.01 (-4.23%)
BA   160.83 (-3.90%)
DIS   124.06 (-3.34%)
S&P 500   3,400.97 (-1.86%)
DOW   27,685.38 (-2.29%)
QQQ   280.47 (-1.50%)
AAPL   115.05 (+0.01%)
MSFT   210.08 (-2.84%)
FB   277.11 (-2.70%)
GOOGL   1,584.29 (-2.98%)
AMZN   3,207.04 (+0.08%)
TSLA   420.28 (-0.08%)
NVDA   525.65 (-3.30%)
BABA   306.87 (-0.98%)
CGC   18.53 (-6.08%)
GE   7.38 (-3.28%)
MU   52.14 (-1.34%)
AMD   82.23 (+0.33%)
T   27.38 (-1.58%)
F   8.03 (-1.59%)
ACB   4.40 (-5.98%)
GILD   59.96 (-1.37%)
NFLX   488.24 (+-0.01%)
NIO   26.01 (-4.23%)
BA   160.83 (-3.90%)
DIS   124.06 (-3.34%)
Log in
NASDAQ:GILD

Gilead Sciences Stock Forecast, Price & News

$59.96
-0.83 (-1.37 %)
(As of 10/26/2020 04:20 PM ET)
Add
Compare
Today's Range
$59.40
Now: $59.96
$60.69
50-Day Range
$60.21
MA: $63.66
$66.34
52-Week Range
$59.40
Now: $59.96
$85.97
Volume10.23 million shs
Average Volume14.73 million shs
Market Capitalization$75.17 billion
P/E RatioN/A
Dividend Yield4.47%
Beta0.55
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a kinase inhibitor; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and AmBisome, an antifungal agent to treat serious invasive fungal infections. In addition, the company offers its products under the name Cayston, Emtriva, Hepsera, Sovaldi, and Tybost. Further, it develops product candidates for the treatment of HIV/AIDS and liver diseases, hematology/oncology, inflammation/respiratory diseases, and others. The company markets its products through its commercial teams; and in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company; Janssen Sciences Ireland UC; Japan Tobacco Inc.; Galapagos NV; Scholar Rock Holding Corporation; Tango Therapeutics; National Cancer Institute; Pfizer, Inc.; Sangamo Therapeutics, Inc.; Gadeta B.V.; HiFiBiO Therapeutics; Agenus Inc.; HOOKIPA Pharma Inc.; Goldfinch Bio, Inc.; and insitro Inc. The company was founded in 1987 and is headquartered in Foster City, California.
Read More
Gilead Sciences logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.1Community Rank: 3.3Dividend Strength: 3.3Insider Behavior: 1.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.73 out of 5 stars

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:GILD
CUSIP37555810
Phone650-574-3000
Employees11,800

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$22.45 billion
Cash Flow$7.22 per share
Book Value$17.90 per share

Profitability

Net Income$5.39 billion

Miscellaneous

Outstanding Shares1,253,724,000
Market Cap$75.17 billion
Next Earnings Date10/28/2020 (Confirmed)
OptionableOptionable
$59.96
-0.83 (-1.37 %)
(As of 10/26/2020 04:20 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive GILD News and Ratings via Email

Sign-up to receive the latest news and ratings for GILD and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Gilead Sciences (NASDAQ:GILD) Frequently Asked Questions

How has Gilead Sciences' stock been impacted by Coronavirus (COVID-19)?

Gilead Sciences' stock was trading at $73.70 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, GILD stock has decreased by 18.6% and is now trading at $59.96.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Gilead Sciences?

27 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gilead Sciences in the last year. There are currently 2 sell ratings, 15 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Gilead Sciences
.

When is Gilead Sciences' next earnings date?

Gilead Sciences is scheduled to release its next quarterly earnings announcement on Wednesday, October 28th 2020.
View our earnings forecast for Gilead Sciences
.

How can I listen to Gilead Sciences' earnings call?

Gilead Sciences will be holding an earnings conference call on Wednesday, October 28th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Gilead Sciences' earnings last quarter?

Gilead Sciences, Inc. (NASDAQ:GILD) issued its quarterly earnings results on Thursday, July, 30th. The biopharmaceutical company reported $1.11 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.57 by $0.46. The biopharmaceutical company had revenue of $5.14 billion for the quarter, compared to analyst estimates of $5.24 billion. Gilead Sciences had a negative net margin of 1.16% and a positive return on equity of 33.59%.
View Gilead Sciences' earnings history
.

How often does Gilead Sciences pay dividends? What is the dividend yield for Gilead Sciences?

Gilead Sciences announced a quarterly dividend on Thursday, July 30th. Shareholders of record on Tuesday, September 15th will be given a dividend of $0.68 per share on Tuesday, September 29th. This represents a $2.72 dividend on an annualized basis and a dividend yield of 4.54%. The ex-dividend date of this dividend is Monday, September 14th.
View Gilead Sciences' dividend history
.

What guidance has Gilead Sciences issued on next quarter's earnings?

Gilead Sciences issued an update on its FY20 earnings guidance on Thursday, July, 30th. The company provided earnings per share guidance of $6.25-7.65 for the period, compared to the Thomson Reuters consensus estimate of $6.69. The company issued revenue guidance of $23.0-25.0 billion, compared to the consensus revenue estimate of $22.54 billion.

What price target have analysts set for GILD?

27 Wall Street analysts have issued 12 month price targets for Gilead Sciences' stock. Their forecasts range from $62.00 to $105.00. On average, they expect Gilead Sciences' share price to reach $78.65 in the next year. This suggests a possible upside of 31.2% from the stock's current price.
View analysts' price targets for Gilead Sciences
.

Has Gilead Sciences been receiving favorable news coverage?

Media headlines about GILD stock have been trending somewhat positive this week, InfoTrie reports. The research group identifies negative and positive media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Gilead Sciences earned a media sentiment score of 1.6 on InfoTrie's scale. They also assigned news coverage about the biopharmaceutical company a news buzz of 5.0 out of 10, meaning that recent media coverage is somewhat likely to have an effect on the stock's share price in the next several days.
View the latest news about Gilead Sciences
.

Who are some of Gilead Sciences' key competitors?

What other stocks do shareholders of Gilead Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Gilead Sciences investors own include NVIDIA (NVDA), The Walt Disney (DIS), Micron Technology (MU), Intel (INTC), Alibaba Group (BABA), Pfizer (PFE), Tesla (TSLA), AbbVie (ABBV), Netflix (NFLX) and Johnson & Johnson (JNJ).

Who are Gilead Sciences' key executives?

Gilead Sciences' management team includes the following people:
  • Ms. Robin L. Washington, CFO & Exec. VP (Age 56)
  • Dr. John G. McHutchison M.D., FRACP, Chief Scientific Officer and Head of R&D (Age 61)
  • Mr. Gregg H. Alton, Chief Patient Officer (Age 53)
  • Ms. Laura Hamill, Exec. VP of Worldwide Commercial Operations (Age 54)
  • Mr. Daniel O'Day, Chairman & CEO (Age 55)

What is Gilead Sciences' stock symbol?

Gilead Sciences trades on the NASDAQ under the ticker symbol "GILD."

Who are Gilead Sciences' major shareholders?

Gilead Sciences' stock is owned by a variety of institutional and retail investors. Top institutional investors include LSV Asset Management (0.37%), Candriam Luxembourg S.C.A. (0.15%), DNB Asset Management AS (0.15%), PGGM Investments (0.13%), Envestnet Asset Management Inc. (0.10%) and Confluence Investment Management LLC (0.10%). Company insiders that own Gilead Sciences stock include Brett A Pletcher, Diane E Wilfong, Gayle E Wilson, Javier Rodriguez, John C Martin, John Francis Cogan, Merdad Parsey, Olsen Per Wold and Richard James Whitley.
View institutional ownership trends for Gilead Sciences
.

Which major investors are selling Gilead Sciences stock?

GILD stock was sold by a variety of institutional investors in the last quarter, including Calamos Advisors LLC, Resources Investment Advisors LLC., Standard Life Aberdeen plc, Transform Wealth LLC, Nisa Investment Advisors LLC, Redpoint Investment Management Pty Ltd, Confluence Investment Management LLC, and First American Trust FSB. Company insiders that have sold Gilead Sciences company stock in the last year include Brett A Pletcher, Diane E Wilfong, Gayle E Wilson, Javier Rodriguez, John Francis Cogan, Merdad Parsey, and Olsen Per Wold.
View insider buying and selling activity for Gilead Sciences
.

Which major investors are buying Gilead Sciences stock?

GILD stock was purchased by a variety of institutional investors in the last quarter, including DNB Asset Management AS, Envestnet Asset Management Inc., State of Alaska Department of Revenue, Candriam Luxembourg S.C.A., PGGM Investments, Conning Inc., Alberta Investment Management Corp, and Greylin Investment Mangement Inc..
View insider buying and selling activity for Gilead Sciences
.

How do I buy shares of Gilead Sciences?

Shares of GILD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Gilead Sciences' stock price today?

One share of GILD stock can currently be purchased for approximately $59.96.

How big of a company is Gilead Sciences?

Gilead Sciences has a market capitalization of $75.17 billion and generates $22.45 billion in revenue each year. The biopharmaceutical company earns $5.39 billion in net income (profit) each year or $6.14 on an earnings per share basis. Gilead Sciences employs 11,800 workers across the globe.

What is Gilead Sciences' official website?

The official website for Gilead Sciences is www.gilead.com.

How can I contact Gilead Sciences?

Gilead Sciences' mailing address is 333 LAKESIDE DRIVE, FOSTER CITY CA, 94404. The biopharmaceutical company can be reached via phone at 650-574-3000 or via email at [email protected]

This page was last updated on 10/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.